China biotech surges as global licensing hits $110b record

By mid-2026, Chinese biotech firms shattered previous records by securing over $110 billion in overseas licensing deals within just six months, a figure that already surpasses 80% of the total for all of 2025. This explosive growth signals an unprecedented global expansion, with deal structures evolving from single star molecule agreements to sophisticated platform-based business development models, reflecting a strategic maturation in how these companies engage international partners.

Leading the charge are pharmaceutical giants like Hengrui Medicine and Fosun Pharma, whose massive R&D investments—exceeding $7.5 billion and generating nearly $1.5 billion in innovative drug revenue respectively—have fueled breakthroughs across oncology, immunology, and neurodegenerative diseases. This blend of robust generics portfolios providing steady cash flow alongside aggressive late-stage innovative drug development underpins sustained global licensing success and positions these firms as formidable players on the world stage.

The surge in cross-border licensing deals has not only eclipsed IPO funding—$110 billion versus roughly $1.8 billion raised through Hong Kong listings in the first half of 2026—but also transformed previously loss-making Chinese biotech companies into profitable enterprises. This shift underscores the critical role of global partnerships in accelerating drug discovery and development, with Chinese assets gaining a reputation for cost-effectiveness that makes them increasingly attractive to multinational pharmaceutical companies, especially as these global players tighten their deal budgets.

High-value transactions involving late-stage clinical assets have diversified beyond oncology to include respiratory, autoimmune, and obesity treatments, exemplified by deals such as Hansoh Pharma’s $2.3 billion out-licensing of its IL-23 receptor antagonist to Aveo Therapeutics and Chengdu Tianqi Pharma’s $1.9 billion licensing of its asthma candidate to AstraZeneca. By focusing on assets with robust clinical data or those nearing regulatory approval, Chinese firms reduce development risks for partners and accelerate timelines, further enhancing their appeal in the fiercely competitive global biotech licensing arena.

Despite significant investments by global pharmaceutical giants like Bristol Myers Squibb and Merck in Chinese biotech—evidenced by deals worth over $17 billion in 2026—strategic partnerships remain complicated by persistent communication gaps and geopolitical tensions. While US firms increasingly rely on China's advanced clinical pipelines and innovation, regulatory hurdles such as the US Biosecure Act impose scrutiny that shapes deal dynamics, creating a delicate balance between collaboration and caution.

The evolving US-China biotech relationship reveals a strategic divergence: although no deals have involved Chinese firms in cutting-edge areas like in vivo cell engineering despite nearly $7 billion in global activity, US pharma companies are nonetheless integrating Chinese innovation in key therapeutic fields such as antibody-drug conjugates and oncology. This dual approach is reflected in companies like Regeneron and Amgen, which maintain robust Chinese partnerships while expanding domestic operations to mitigate geopolitical risks.

Big Pharma's acquisition strategy is shifting from buying entire biotech companies to selectively licensing late-stage drug assets, a trend that Chinese biotechs are adapting to by developing 'portable therapeutic packages' that reduce uncertainty and fit seamlessly into global pharma's infrastructure. This asset-centric approach is underscored by Pfizer's $1.25 billion deal for SSGJ 707 rights and Sanofi's targeted subsidiary acquisition, contributing to Chinese licensors accounting for 40% of global pharma licensing assets in 2025, up from under 30% the previous year.

Chinese biotech's meteoric rise—from representing just 2% of global deal flow to commanding 50% within five years—is fueled by strategic partnerships with US pharma that foster a collaborative ecosystem accelerating drug development and lowering costs. This surge is driven by China's large patient population enabling faster, cheaper clinical trials, the return of US-trained scientists, and strong government and venture capital support, positioning Chinese firms as pivotal out-licensors of innovative molecules to Western companies.

In the rapidly evolving landscape of China-origin biotech licensing, control over intellectual property has emerged as the pivotal battleground, often eclipsing the scientific merits of the assets themselves. Industry experts like Paul Calvo of Sterne Kessler emphasize that the strategic focus has shifted decisively toward securing ownership and rights to the underlying IP, as this control ultimately dictates long-term value capture and competitive advantage. This shift reflects a broader recognition among global partners that mastering IP governance is essential to navigating the complex cross-border deal environment and safeguarding innovation-driven growth.